Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

• Mariano Severgnini,
• Rizwan Haq,
• Anita Giobbie-Hurder,
• Scott J Rodig,
• Patrick A Ott,
• Evisa Gjini,
• Ryan J Sullivan,
• Donald P Lawrence,
• Matthew Nazzaro,
• Kathleen L Pfaff,
• Jacquelyn O Wolff,
• Elizabeth I Buchbinder

Affiliations

Mariano Severgnini

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Rizwan Haq

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Anita Giobbie-Hurder

Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Scott J Rodig

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Patrick A Ott

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Evisa Gjini

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Ryan J Sullivan

Harvard Medical School, Boston, Massachusetts, USA

Donald P Lawrence

Harvard Medical School, Boston, Massachusetts, USA

Matthew Nazzaro

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Kathleen L Pfaff

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Jacquelyn O Wolff

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Elizabeth I Buchbinder

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA